




## Curriculum Vitae

*\* CV must be written in English*

Personal Information	
Title (i.e. Pf., Dr., etc.)	Prof.
Name (First Name/ Middle Name /Last Name)	Chang Hwan CHOI
Degree (i.e. MD, MSc, PhD, etc.)	MD, PhD
Country	Korea
Affiliation	Chung-Ang University College of Medicine
E-mail	gicch@cau.ac.kr
	
Educational Background	
<p>- Sep. 2001 ~ Aug. 2004 Yonsei University College of Medicine Doctorate Course: Graduated Major: Gastroenterology</p> <p>- Mar. 1999 ~ Feb. 2001 Yonsei University College of Medicine Master's Course: Graduated Major: Internal medicine</p> <p>- Mar. 1991~ Feb. 1997 Yonsei University College of Medicine: Graduated</p>	
Professional Career	
<p>- Mar. 2015 ~ present Professor in Gastroenterology, Internal Medicine (Subspecialty: lower gastrointestinal diseases): Chung-Ang University College of Medicine</p> <p>- July 2013 ~ June 2014 Visiting Scholar in Gastroenterology, University of North Carolina, School of Medicine at Chapel Hill</p> <p>- Mar. 2010 ~ Feb. 2015 Associate Professor in Gastroenterology (Subspecialty: lower gastrointestinal diseases): Chung-Ang University College of Medicine</p> <p>- Mar. 2006 ~ Feb. 2010 Assistant Professor in Gastroenterology (Subspecialty: lower gastrointestinal diseases): Chung-Ang University College of Medicine</p> <p>- Mar. 2004 ~ Feb. 2006 Assistant Professor in Gastroenterology (Subspecialty: lower gastrointestinal diseases): Kwandong University College of Medicine</p> <p>- Mar. 2002 ~ Feb. 2004 Clinical Fellowship (Subspecialty: Gastroenterology) Division of Gastroenterology, Department of Internal Medicine, Yonsei University Severance Hospital in Seoul, South Korea Subspecialty board for Gastroenterology Acquired</p> <p>- Mar. 1997 ~ Feb. 2002 Yonsei University Severance Hospital, Dept. of Internal Medicine: Intern and Resident Course Medical Specialist in Internal Medicine Acquired</p>	



<b>Research Field</b>
Inflammatory bowel disease, Irritable bowel syndrome, Gut microbiota
<b>Main Scientific Publications</b>
<ol style="list-style-type: none"> <li>1. Moon JM, Kwon KE, Lee JW, Minn KR, Kim K, Seo J, Shin SY, Jung SY, Choi CH. Risk of avascular necrosis in patients with inflammatory bowel disease: Insights from a nationwide cohort study and the impact of corticosteroid use. <i>Dig Liver Dis.</i> 2025 Jan;57(1):176-183.</li> <li>2. Oh HN, Shin SY, Kim JH, Baek J, Kim HJ, Lee KM, Park SJ, Kim SY, Choi HK, Kim W, Sul WJ, Choi CH. Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets. <i>Gut Pathog.</i> 2024 Aug 26;16(1):44.</li> <li>3. Shin SY, Kim HS, Kim K, Choi CW, Moon JM, Kim JW, Joo HJ, Seo J, Sung M, Choi CH. Histologic features and predicting prognosis in ulcerative colitis patients with mild endoscopic activity. <i>Korean J Intern Med.</i> 2024 Jan;39(1):68-76.</li> <li>4. Kim SY, Shin SY, Saeed M, Ryu JE, Kim JS, Ahn J, Jung Y, Moon JM, Choi CH, Choi HK. Prediction of Clinical Remission with Adalimumab Therapy in Patients with Ulcerative Colitis by Fourier Transform-Infrared Spectroscopy Coupled with Machine Learning Algorithms. <i>Metabolites.</i> 2023 Dec 19;14(1):2.</li> <li>5. Kim SY, Shin SY, Park SJ, Im JP, Kim HJ, Lee KM, Kim JW, Jung SA, Lee J, Kang SB, Shin SJ, Kim ES, Kim YS, Kim TO, Kim HS, Park DI, Kim HK, Kim ES, Kim YH, Teng D, Kim JH, Kim W, Saeed M, Moon JM, Kim K, Choi CH, Choi HK. Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis. <i>Therap Adv Gastroenterol.</i> 2023 May 2;16:17562848231168199.</li> <li>6. Shin SH, Oh K, Hong SN, Lee J, Oh SJ, Kim ES, Na SY, Kang SB, Koh SJ, Bang KB, Jung SA, Jung SH, Kim KO, Park SH, Yang SK, Choi CH, Ye BD. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study. <i>Therap Adv Gastroenterol.</i> 2023 Mar 18;16:17562848231154103.</li> <li>7. Shin SY, Kim Y, Kim WS, Moon JM, Lee KM, Jung SA, Park H, Huh EY, Kim BC, Lee SC, Choi CH; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease. <i>Intest Res.</i> 2023 Jan;21(1):148-160.</li> <li>8. Na SY, Choi CH, Song EM, Bang KB, Park SH, Kim ES, Park JJ, Keum B, Lee CK, Lee BI, Ryoo SB, Koh SJ, Choi M, Kim JS; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. <i>Intest Res.</i> 2023 Jan;21(1):61-87.</li> <li>9. Shin SY, Park S, Moon JM, Kim K, Kim JW, Chun J, Lee TH, Choi CH; Microbiome Research Group of the Korean Society for Neurogastroenterology and Motility. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial. <i>J Neurogastroenterol Motil.</i> 2022 Oct 30;28(4):642-654.</li> <li>10. Yu J, Park SJ, Kim HW, Lim YJ, Park J, Cha JM, Ye BD, Kim TO, Kim HS, Lee HS, Jung SY, Kim Y, Choi CH. Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study. <i>Gut Liver.</i> 2022 Sep 15;16(5):764-774.</li> <li>11. Shin SY, Park SJ, Kim Y, Im JP, Kim HJ, Lee KM, Kim JW, Jung SA, Lee J, Kang SB, Shin SJ, Kim ES, Kim YS, Kim TO, Kim HS, Park DI, Kim HK, Kim ES, Kim YH, Kim DH, Teng D, Kim JH, Kim W, Choi CH; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study. <i>Intest Res.</i> 2022 Jul;20(3):350-360.</li> </ol>